Allakos Inc. (NASDAQ:ALLK – Get Free Report) was the recipient of a significant decrease in short interest in February. As of February 28th, there was short interest totalling 1,940,000 shares, a decrease of 18.8% from the February 13th total of 2,390,000 shares. Approximately 2.6% of the company’s stock are sold short. Based on an average daily volume of 2,190,000 shares, the short-interest ratio is currently 0.9 days.
Analyst Ratings Changes
ALLK has been the subject of a number of recent analyst reports. Citizens Jmp cut shares of Allakos from a “strong-buy” rating to a “hold” rating in a report on Monday, January 27th. Piper Sandler cut shares of Allakos from a “strong-buy” rating to a “hold” rating in a report on Monday, January 27th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, Allakos has an average rating of “Hold” and an average target price of $2.00.
View Our Latest Stock Analysis on Allakos
Institutional Investors Weigh In On Allakos
Allakos Price Performance
ALLK stock opened at $0.25 on Tuesday. Allakos has a 52-week low of $0.23 and a 52-week high of $1.56. The company has a 50-day moving average of $0.47 and a two-hundred day moving average of $0.78. The stock has a market capitalization of $22.68 million, a price-to-earnings ratio of -0.13 and a beta of 0.72.
About Allakos
Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.
Read More
- Five stocks we like better than Allakos
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Microsoft’s AI Strategy Eases Analyst Concerns—Is It a Buy?
- Upcoming IPO Stock Lockup Period, Explained
- CrowdStrike Stock Attracts Congressional Buyers—Time to Invest?
- 3 Warren Buffett Stocks to Buy Now
- ARK Innovation Fund Bets Big on Bitcoin—Will It Pay Off?
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.